Breathe easier: Advanced Inhalation sets terms for $10 million IPO

Advanced Inhalation Therapies (AIT), which is developing inhaled nitric oxide drug-device therapies for respiratory infections, announced terms for its IPO on Monday. 

The Rehovot, Israel-based company plans to raise $10 million by offering 675,000 units at a price of $15; each unit represents two shares of common stock and three warrants exercisable at 125% of the offering price. At the proposed price, Advanced Inhalation Therapies (AIT) would command a fully diluted market value of $34 million. 

With the proposed market cap below $50 million, this deal will be excluded from our IPO stats.

Advanced Inhalation Therapies (AIT), which was founded in 2011, plans to list on the Nasdaq under the symbol AITPU. The warrants will list under the symbol AITPW. Joseph Gunnar & Co. is the sole bookrunner on the deal, replacing Aegis Capital.